Imperagen raises £5 million to use quantum physics, AI on enzyme engineering

Biotech company Imperagen announced on Thursday a £5 million ($6.7 million) seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone. The company was founded in 2021 by Manchester Institute of Biotechnology scientists Dr. Andrew Currin, Dr. Tim Eyes, and Dr. Andy Almond and spun out of the university. The startup seeks to improve enzyme engineering by making it faster, more efficient, and less costly than the slower, more physical, trial-and-error-focused process used now.